PDT Partners LLC Makes New $828,000 Investment in AnaptysBio, Inc. $ANAB

Key Points

• PDT Partners LLC has acquired a new position in AnaptysBio, Inc., purchasing 44,529 shares valued at approximately $828,000, representing 0.15% ownership of the company.
• Several institutional investors have recently increased their stakes in AnaptysBio, including HighMark Wealth Management LLC and Sanofi, with the latter investing about $10.88 million.
• A number of analysts have raised their price targets for AnaptysBio, with forecasts now ranging from $20.00 to $90.00, reflecting growing market confidence in the stock's performance.

PDT Partners LLC acquired a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,529 shares of the biotechnology company's stock, valued at approximately $828,000. PDT Partners LLC owned approximately 0.15% of AnaptysBio as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ANAB. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,531 shares in the last quarter. Northern Trust Corp grew its holdings in AnaptysBio by 10.0% during the 4th quarter. Northern Trust Corp now owns 219,986 shares of the biotechnology company's stock valued at $2,913,000 after purchasing an additional 20,073 shares in the last quarter. Bridgefront Capital LLC acquired a new stake in AnaptysBio during the 4th quarter valued at $252,000. Deutsche Bank AG grew its holdings in AnaptysBio by 52.0% during the 4th quarter. Deutsche Bank AG now owns 17,867 shares of the biotechnology company's stock valued at $237,000 after purchasing an additional 6,113 shares in the last quarter. Finally, Fairmount Funds Management LLC acquired a new position in shares of AnaptysBio in the 4th quarter valued at about $24,050,000.

Insider Buying and Selling at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of AnaptysBio stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total value of $493,202.25. Following the transaction, the director directly owned 4,965 shares of the company's stock, valued at $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 33.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ANAB shares. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Guggenheim reiterated a "buy" rating and issued a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. UBS Group reiterated a "neutral" rating and issued a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Wedbush lifted their price objective on shares of AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Finally, HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.13.

AnaptysBio Trading Up 0.6%

Shares of NASDAQ ANAB traded up $0.13 during midday trading on Tuesday, reaching $22.32. The company's stock had a trading volume of 125,354 shares, compared to its average volume of 736,880. The company has a 50 day moving average price of $23.13 and a 200 day moving average price of $20.96. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $40.70. The company has a market cap of $624.96 million, a price-to-earnings ratio of -4.98 and a beta of -0.19.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.16. The business had revenue of $22.26 million for the quarter, compared to the consensus estimate of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. Research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.